Serum squamous cell carcinoma antigen and CYFRA 21-1 in cervical cancer treatment

International Journal of Radiation Oncology Biology Physics

Volumn 52, Issue 1, 2002, Pages 23-32

  Pras, Elisabeth ^a   Willemse, Pax H B ^a   Canrinus, Alof A ^a   De Bruijn, Henk W A ^a   Sluiter, Wim J ^a   Ten Hoor, Klaske A ^a   Aalders, Jan G ^a   Szabo, Ben G ^a   De Vries, Elisabeth G E ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Cervical carcinoma; Chemoradiation; CYFRA 21 1; SCC; Squamous cell carcinoma antigen

Indexed keywords

ANTIGENS; CELLS; CHEMOTHERAPY; TUMORS;

ADDITIVE SURGERY;

RADIOTHERAPY;

CARBOPLATIN; CYTOKERATIN 19 FRAGMENT; FLUOROURACIL; SQUAMOUS CELL CARCINOMA ANTIGEN; TUMOR MARKER;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BEAM THERAPY; BLOOD ANALYSIS; BRACHYTHERAPY; CANCER STAGING; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME IMMUNOASSAY; FEMALE; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; MICROPARTICLE ENZYME IMMUNOASSAY; PRIORITY JOURNAL; PROGNOSIS; RADIOTHERAPY; RECURRENCE RISK; SURVIVAL; TUMOR BIOPSY; TUMOR VOLUME; UTERINE CERVIX CANCER;

ADULT; AGED; ANTIGENS, NEOPLASM; COMBINED MODALITY THERAPY; FEMALE; HUMANS; KERATINS; MIDDLE AGED; NEOPLASM STAGING; SERPINS; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 0036139503     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(01)01805-3     Document Type: Article

References (48)

1. Chemotherapy as initial treatment for cervical carcinoma; Clinical and tumor marker response
2. Concomitant chemoradiation prior to surgery in the treatment of advanced cervical carcinoma
3. If and when? The role of chemotherapy in locally advanced carcinoma of the cervix
4. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage Ib cervical carcinoma
5. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer
6. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer
7. A randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stages IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes
8. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix
9. Pretreatment squamous cell carcinoma antigen; A newly identified prognostic factor in early-stage cervical cancer
10. Clinical value of pretreatment serum Cyfra 21-1, tissue polypeptide antigen, and squamous cell carcinoma antigen levels in patients with cervical cancer
11. Improvement of clinical staging in cervical cancer with serum squamous cell carcinoma antigen and CA 125 determinations
12. Radioimmunoassay for tumor antigen of human cervical squamous cell carcinoma
13. Tumor associated antigen TA-4, in the monitoring of the effects of therapy for squamous cell carcinoma of the uterine cervix
14. Prognostic significance of pretreatment squamous cell carcinoma antigen and carcinoembryonic antigen in squamous cell carcinoma of the uterine cervix
15. Cervical carcinoma; A comparison of four potential biochemical tumor markers
16. Cancer of the uterine cervix; Clinical value of squamous cell carcinoma antigen (SCC) measurements
17. Squamous cell carcinoma antigen and carcinoembryonic antigen levels as prognostic factors for the response of cervical carcinoma to chemotherapy
18. Squamous cell carcinoma (SCC) antigen in patients with invasive cervical carcinoma during primary irradiation
19. Serum squamous cell carcinoma antigen in the monitoring of radiotherapy response in carcinoma of the cervix
20. Squamous cell carcinoma antigen, tumor-associated trypsin inhibitor, and carcinoembryonic antigen for monitoring cervical cancer
21. Prognostic significance of serum fragments of cytokeratin 19 measured by CYFRA 21-1 in cervical cancer
22. Cancer of the uterine cervix; Sensitivity and specificity of serum Cyfra 21.1 determinations
23. Cytokeratin subunit 19 measured by CYFRA 21-1 assay in follow-up of cervical cancer
24. The clinical value of SCC antigen in cancer of the uterine cervix
25. Serum level of squamous cell carcinoma antigen and tumor size are useful to identify preoperatively patients at high risk of cervical cancer
26. Concurrent chemo- and radiotherapy in patients with locally advanced carcinoma of the cervix
27. Non-parametric estimation from incomplete observations
28. Prognostic significance of pretreatment serum levels of squamous cell carcinoma antigen and CA-125 in cervical carcinoma
29. Squamous cell carcinoma antigen; Clinical utility in squamous cell carcinoma of the uterine cervix
30. Squamous cell carcinoma antigen (SCC-A) values related to clinical outcome of pre-invasive and invasive cervical carcinoma
31. Cancer of the uterine cervix; Sensitivity and specificity of serum squamous cell carcinoma antigen determinations
32. The prognostic value of TPA and SCC in squamous cell carcinoma of the cervix
33. Serum squamous cell carcinoma antigen levels in invasive cervical cancer; Prediction of response and recurrence
34. Multiple tumour marker assays in advanced cervical cancer; Relationship to chemotherapy response and clinical outcome
35. Correlation of squamous cell carcinoma antigen levels and treatment response in cervical cancer
36. Serum tumour markers in carcinoma of the uterine cervix and outcome following radiotherapy
37. Adenocarcinoma of the uterine cervix; Prognostic significance of pretreatment serum CA 125, squamous cell carcinoma antigen, and carcinoembryonic antigen levels in relation to clinical and histopathologic tumor characteristics
38. Cytokeratin fragment 21-1 in gynecologic malignancy; Comparison with cancer antigen 125 and squamous cell carcinoma-related antigen
39. Value of squamous cell carcinoma antigen levels in invasive cervical carcinoma
40. Use of serum squamous cell carcinoma antigen assays in chemotherapy treatment of cervical cancer
41. The value of squamous cell carcinoma antigen in patients with locally advanced cervical cancer undergoing neoadjuvant chemotherapy
42. An evaluation of squamous cell carcinoma antigen in patients with cervical squamous cell carcinoma
43. Squamous cell carcinoma antigen; Prognostic significance and role in the monitoring of neoadjuvant chemotherapy response in cervical cancer
44. Monitoring the course of cervical carcinoma with the squamous cell carcinoma serum radioimmunoassay
45. The prognostic significance of pre- and posttreatment SCC levels in patients with squamous cell carcinoma of the cervix treated by radiotherapy
46. Relationship between squamous cell carcinoma antigen levels and tumor volumes in patients with cervical carcinomas undergoing neoadjuvant chemotherapy
47. Squamous cell carcinoma antigen in serum for monitoring of head and neck and uterine cervical squamous cell carcinomas after radiotherapy
48. Prognostic significance of serum tumour markers in carcinoma of the cervix